These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?The Motley Fool • 12/05/25
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat TumorsBenzinga • 12/04/25
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)Business Wire • 12/04/25
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
30% of the S&P 500 Is Mag 7 Tech Stocks, but This ETF Refuses to Own a Single One24/7 Wall Street • 12/02/25
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025Business Wire • 12/01/25
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth BuildersThe Motley Fool • 11/30/25
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder CancerZacks Investment Research • 11/24/25
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic ApproachesBusiness Wire • 11/24/25
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder CancerBusiness Wire • 11/21/25